Elevance Health vs Oscar Health
ELV and OSCR side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELV and OSCR compare
Elevance Health is the larger company, worth 9.7 times as much as Oscar Health ($91.1B against $9.4B).
On earnings, Elevance Health is cheaper: it trades at 18.7× trailing earnings, against 21.7× for Oscar Health.
Oscar Health grew revenue faster over the last twelve months (42.8% versus 6.3% for Elevance Health).
Oscar Health keeps more of each dollar of sales as profit, with a net margin of 3.6% compared with 2.5% at Elevance Health.
Elevance Health pays a dividend yielding 1.6%; Oscar Health does not pay one.
Elevance Health scores higher on the StockData Score (15 against 11 for Oscar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELV | OSCR |
|---|---|---|
| Size and price | ||
| Market cap | $91.1B | $9.4B |
| Share price | $420.07 | $30.37 |
| Change, 1 year | 24.9% | 60.6% |
| Change, 5 years | −0.47% | 78.6% |
| Beta (5Y) | 0.44 | 1.65 |
| Employees | 97K | 2,305 |
| StockData Score | ||
| Total score | 15 (better) | 11 |
| Valuation score | 4 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 3 | 4 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 18.7× (better) | 21.7× |
| P/S | 0.5× (better) | 0.6× |
| P/B | 2.0× (better) | 4.6× |
| EV/EBITDA | 12.4× | 1.9× (better) |
| P/FCF | 14.5× | 2.1× (better) |
| PEG | 14.81 | – |
| FCF yield | 6.9% | 46.7% (better) |
| Fair value | $477.08 | $23.67 |
| Margin of safety | 11.9% (better) | −28.3% |
| Growth | ||
| Revenue growth (TTM) | 6.3% | 42.8% (better) |
| Revenue growth, 5Y average | 10.3% | 90.8% (better) |
| Net income growth (TTM) | −7.4% | – |
| EPS growth (TTM) | −4.3% | – |
| EPS growth, 5Y average | 7.0% | – |
| Profitability | ||
| Gross margin | 89.1% | – |
| Operating margin | 2.7% | 4.1% (better) |
| Net margin | 2.5% | 3.6% (better) |
| FCF margin | 3.1% | 28.6% (better) |
| Return on equity | 11.2% | 34.3% (better) |
| Return on invested capital | 11.5% | – |
| Financial health | ||
| Debt / equity | 0.69 | 0.21 (better) |
| Net debt / EBITDA | −0.70 | −12.35 |
| Interest coverage | 3.8× | 39.7× (better) |
| Current ratio | 1.52 (better) | 1.08 |
| Altman Z-score | 3.03 (better) | 1.95 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.6% | – |
| Payout ratio | 30.3% | – |
| Buyback yield | 3.0% | – |
| Shareholder yield | 4.6% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 94.0% | 64.7% |
| Held by insiders | 0.19% | 20.9% |
| Insider net buying, 12 months | $493K (better) | −$138M |
| Superinvestors holding | 8 | – |
| Short interest, % of float | 2.2% | 6.7% |
Go deeper
- ELV stock overview
- ELV income statement
- ELV valuation and score
- OSCR stock overview
- OSCR income statement
- OSCR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.